الفهرس 
A pharmaceutical study for the treatment of an ocular disorder
List of contentsOnly 14 pages are availabe for public view
 |  | from | 186 |  |  |
| | | from | 186 | | |
Abstract
Fungal keratitis is a corneal tissue severe infection resulting from fungal species as Fusarium, Aspergillus or candida. If the treatment is delayed, severe corneal ulceration and loss of vision could happen. Voriconazole (VCZ) has a relatively wide spectrum of activity. It is a relatively hydrophobic drug (Log P = 1.65) with a limited solubility in water (0.50 mg/mL). Comparing VCZ to other antifungal drugs, it was found to be tremendously active against filamentous and dimorphic fungi with significantly lower minimum inhibitory concentration. Besides, VCZ is well-tolerated and efficient in the prevention of diseases refractory to other antifungals. Previously performed studies on the in vitro activity of VCZ showed its complete activity against different fungal isolates correlated to keratitis and endophthalmitis. Also, it was found to have outstanding activity against keratitis after topical administration. So, all over the characteristics of VCZ makes it an effective drug for the treatment of fatal mycoses. VCZ suspension showed short residence time after ocular application. This could increase the frequency of administration and reduce patient compliance, which is considered as a common drawback of ocular drug delivery systems.The aim of this study was to enhance the permeation and control the delivery of voriconazole